In conclusion, our systematic review found that TRPV1, TRPA1 and TRPM8 agonists have beneficial effects for patients with neurogenic oropharyngeal dysphagia when compared to placebo interventions. This evidence concerns the gene TRPA1 and Oral-pharyngeal dysphagia.